Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465654 | 0.89 | FFAR1 (0.47) | KMT2AFFAR1F2ELANE | |
| SCHEMBL6460113 | 0.81 | CTNNB1 (0.36) | KMT2ACTNNB1MAPK1SMN1; SMN2F2 | |
| SCHEMBL6465718 | 0.80 | L3MBTL1 (0.40) | HTTCTNNB1MAPK1SMN1; SMN2GPR88 | |
| SCHEMBL31467205 | 0.77 | HTT (0.48) | KMT2AHTTFFAR1SMN1; SMN2 | |
| SCHEMBL435332 | 0.77 | ESR1 (0.51) | KMT2AHTT | |
| SCHEMBL14886863 | 0.77 | ESR1 (0.51) | KMT2AHTT | |
| SCHEMBL30529996 | 0.76 | L3MBTL1 (0.46) | KMT2AHTTFFAR1 | |
| SCHEMBL27904916 | 0.75 | KCNA5 (0.47) | KMT2AHTT | |
| SCHEMBL27879125 | 0.75 | KCNA5 (0.47) | KMT2AHTT | |
| SCHEMBL27862776 | 0.75 | KCNA5 (0.47) | KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1474400-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068756-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | F7, HABP2, F13B | KMT2A 1487/4885HTT 3263/4885CTNNB1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.